In the EU, Japan and the US, Sarclisa plus Pd is approved ... accepted a supplemental biologics licence application of Sanofi and Regeneron’s Dupixent, for priority review, with a decision ...

Regeneron has announced that the European Commission ... Gynaecological Oncological Trial groups (ENGOT), and NRG Oncology-Japan. Patients were of a median age of 51 years old – 78% with ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court ...

Feb 24 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between 10 months and 16 years old ...

Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led ...

Regeneron has moved closer to a regulatory filing for its BCMAxCD3 bispecific antibody linvoseltamab, the first of a series of bispecifics that is spearheading its oncology pipeline. New data from ...